SURF insider filings
Surface Oncology, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-09-08. Screen SURF transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for SURF between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Surface Oncology, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-09-08 | 4 | FEES JESSICA — Chief Financial Officer | Disposition to issuer (D): 101,915 · Disposition to issuer (D): 150,000 (derivative) @ $0 | EDGAR |
| 2023-09-08 | 4 | Adams Chandra — Deputy GC | Disposition to issuer (D): 23,884 · Disposition to issuer (D): 50,000 (derivative) @ $0 · Disposition to issuer (D): 50,000 (derivative) @ $0 | EDGAR |
| 2023-09-08 | 4 | RATH HENRY C. — Chief Business Officer | Disposition to issuer (D): 44,971 · Disposition to issuer (D): 150,000 (derivative) @ $0 | EDGAR |
| 2023-09-08 | 4 | ROSS ROBERT W. — Chief Executive Officer, Director | Disposition to issuer (D): 83,193 · Disposition to issuer (D): 400,000 (derivative) @ $0 | EDGAR |
| 2023-09-08 | 4 | GRAYZEL DAVID S. — Director | Disposition to issuer (D): 2,945,453 | EDGAR |
| 2023-09-08 | 4 | Sigal Charles Elliott — Director | Disposition to issuer (D): 45,453 · Disposition to issuer (D): 113,636 (derivative) @ $0 | EDGAR |
| 2023-09-08 | 4 | Goater Jeff — Director | Disposition to issuer (D): 129,222 | EDGAR |
| 2023-09-08 | 4 | Palombella Vito J. — Chief Scientific Officer | Disposition to issuer (D): 87,212 · Disposition to issuer (D): 150,000 (derivative) @ $0 | EDGAR |
| 2023-09-08 | 4 | ONEILL ALISON — Chief Medical Officer | Disposition to issuer (D): 56,686 · Disposition to issuer (D): 150,000 (derivative) @ $0 | EDGAR |
| 2023-08-11 | 4 | Adams Chandra — Deputy GC | Sale (S): 3,901 @ $0.94 | EDGAR |
| 2023-08-11 | 4 | FEES JESSICA — Chief Financial Officer | Sale (S): 9,434 @ $0.94 | EDGAR |
| 2023-08-11 | 4 | ROSS ROBERT W. — Chief Executive Officer | Sale (S): 16,713 @ $0.94 | EDGAR |
| 2023-08-11 | 4 | ONEILL ALISON — Chief Medical Officer | Sale (S): 7,042 @ $0.94 | EDGAR |
| 2023-03-03 | 4 | RATH HENRY C. — Chief Business Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | ROSS ROBERT W. — Chief Executive Officer | Grant/award (A): 400,000 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | Adams Chandra — Deputy GC | Grant/award (A): 50,000 (derivative) @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | FEES JESSICA — Chief Financial Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | Palombella Vito J. — Chief Scientific Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2023-03-03 | 4 | ONEILL ALISON — Chief Medical Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2022-11-03 | 4 | Adams Chandra — Deputy GC | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2022-08-05 | 4 | RATH HENRY C. — Chief Business Officer | Sale (S): 5,676 @ $1.72 | EDGAR |
| 2022-08-05 | 4 | ROSS ROBERT W. — Chief Executive Officer | Sale (S): 10,594 @ $1.72 | EDGAR |
| 2022-08-05 | 4 | FEES JESSICA — Chief Financial Officer | Sale (S): 5,980 @ $1.72 | EDGAR |
| 2022-08-05 | 4 | Palombella Vito J. — Chief Scientific Officer | Sale (S): 4,463 @ $1.72 | EDGAR |
| 2022-08-05 | 4 | ONEILL ALISON — Chief Medical Officer | Sale (S): 4,463 @ $1.72 | EDGAR |
| 2022-06-30 | 4 | Brunn Carsten — Director | Grant/award (A): 48,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Torres Denice — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Hickey Benjamin — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Ibrahim Ramy — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | GRAYZEL DAVID S. — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Sigal Charles Elliott — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Goater Jeff — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Shanafelt Armen — Director, 10% owner | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Stelzer Laurie — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2022-04-01 | 4 | Boni Theresa — General Counsel & Secretary | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2022-03-03 | 4 | ROSS ROBERT W. — Chief Executive Officer | Grant/award (A): 56,000 @ $0 · Grant/award (A): 359,000 (derivative) @ $0 | EDGAR |
| 2022-03-03 | 4 | RATH HENRY C. — Chief Business Officer | Grant/award (A): 38,000 @ $0 · Grant/award (A): 108,000 (derivative) @ $0 | EDGAR |
| 2022-03-03 | 4 | FEES JESSICA — Chief Financial Officer | Grant/award (A): 38,000 @ $0 · Grant/award (A): 108,000 (derivative) @ $0 | EDGAR |
| 2022-03-03 | 4 | Palombella Vito J. — Chief Scientific Officer | Grant/award (A): 38,000 @ $0 · Grant/award (A): 108,000 (derivative) @ $0 | EDGAR |
| 2022-03-03 | 4 | ONEILL ALISON — Chief Medical Officer | Grant/award (A): 38,000 @ $0 · Grant/award (A): 108,000 (derivative) @ $0 | EDGAR |
| 2022-01-14 | 4 | FEES JESSICA — Chief Financial Officer | Sale (S): 19,854 @ $6.10 | EDGAR |
| 2022-01-14 | 4 | ROSS ROBERT W. — Chief Executive Officer | Sale (S): 33,500 @ $6.10 | EDGAR |
| 2022-01-14 | 4 | Nogelo Liisa I — Chief Legal Officer | Sale (S): 26,325 @ $6.10 | EDGAR |
| 2022-01-14 | 4 | Goater Jeff — Director | Sale (S): 127,778 @ $6.10 | EDGAR |
| 2022-01-14 | 4 | Palombella Vito J. — Chief Scientific Officer | Sale (S): 26,325 @ $6.10 | EDGAR |
| 2022-01-14 | 4 | ONEILL ALISON — Chief Medical Officer | Grant/award (A): 45,000 @ $0 · Sale (S): 14,809 @ $6.10 | EDGAR |
| 2022-01-05 | 4 | Hickey Benjamin — Director | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | Torres Denice — Director | Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2021-08-03 | 4 | Torres Denice — Director | Grant/award (A): 36,000 (derivative) @ $0 | EDGAR |
| 2021-06-11 | 4 | Goater Jeff — Director | Option exercise (M): 200,000 @ $4.14 · Option exercise (M): 34,727 @ $4.14 · Sale (S): 234,727 @ $7.66 · Option exercise (M): 10,273 @ $4.14 · Sale (S): 15,273 @ $7.61 · Option exercise (M): 200,000 (derivative) @ $0 · +2 more | EDGAR |
Recent 8-K events — Surface Oncology, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2023-09-08 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-08-30 | 8-K | 8.01 — Other Events | EDGAR |
| 2023-08-02 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-07-10 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2023-07-03 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-06-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-05-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-03-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-02-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2023-01-12 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SURF returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs